BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Minghui Pharma announces oncology agreement worth $185 M with Qilu Pharma in Greater China

May 10, 2025 | News

MHB088C is an innovative B7-H3-targeted antibody-drug conjugate (ADC) developed by Minghui Pharma



Minghui Pharmaceutical, a late-stage clinical biopharmaceutical company, has announced an exclusive licensing and collaboration agreement with Qilu Pharmaceutical for the development, manufacturing, and commercialisation of its B7-H3 ADC (MHB088C) in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan).

Under the agreement, Qilu will obtain exclusive rights to MHB088C in the region, while Minghui will beeligible for total payments of up to 1.345 billion RMB ($185 million), including: 280 million RMB upfront and a near-term milestone payment, 1.065 billion RMB in development, regulatory and sales milestone payments, and up to double-digit royalties on net product sales. Minghui will retain global rights to MHB088C outside Greater China and continue advancing its development in these regions.

MHB088C is an innovative B7-H3-targeted antibody-drug conjugate (ADC) developed using Minghui's proprietary SuperTopoi ADC platform. It is distinguished by its potent anti-tumour activity and superior safety profile, significantly expanding the therapeutic window.

In ongoing Phase Ã¢â?¦Â /Ã¢â?¦Â¡ clinical trials, MHB088C has been evaluated in over 300 patients with advanced or metastatic solid tumors, demonstrating a favorable safety profile and promising efficacy. Subgroup analyses in small cell lung cancer (SCLC) and metastatic castration-resistant prostate cancer (mCRPC) will be presented at the ASCO 2025 Annual Meeting as oral and poster presentations, respectively. A Phase Ã¢â?¦Â¢ trial in relapsed SCLC has been officially initiated in China, with the first patient being enrolled in a couple of weeks.

Dr Guoqing Cao, CEO of Minghui said, "MHB088C has demonstrated robust efficacy with great safety profiles, with no major hematological toxicity or ILD, positioning the program as a best-in-class B7-H3 ADC. With Qilu's leadership and resources, we are confident that MHB088C will serve patients in need and contribute to the advancement of precision oncology inChina."